Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension, Deep Phenotyping
The PAH Platform for Deep Phenotyping in Korean Subjects
A total of 16 regional hospitals will be registering clinical data and biological specimens of idiopathic pulmonary arterial hypertension (IPAH)/heritable pulmonary arterial hypertension (HPAH) patients across Korea.
- Conditions
- Pulmonary Arterial Hypertension, Deep Phenotyping, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
- Trial name
- PHOENIKS (NCT03933579)
- Testing
- Deep phenotyping
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Gachon University Gil Medical Center
Pulmonary Arterial Hypertension, Healthy
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand [11C]PBR28) in the lungs of patients living with PAH relative to age matched controls.
- Trial name
- NCT05745961
- Testing
- TSPO PET scan (11C-PBR28)
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.
- Trial name
- RAPID (NCT02847260)
- Testing
- Remodulin
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Arterial Hypertension
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
- Trial name
- NCT07558460
- Testing
- Virtual Reality Group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Hypertension, Pulmonary
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy.
- Trial name
- NCT00458042
- Testing
- treprostinil sodium
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
The investigators are doing this research study to find out how blood flow changes in the lungs of people with pulmonary hypertension before and after treatment with ambrisentan (sold under the brand name Letairis).
- Trial name
- NCT02958358
- Testing
- CT imaging, functional PET imaging
- Where
- United States
- Sponsor
- Robert Scott Harris, M.D.
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION
HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided…
- Trial name
- HYPID-2 (NCT02799771)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology).
- Trial name
- NCT00367770
- Testing
- Tracleer®
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 37 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the…
- Trial name
- NCT02657356
- Testing
- Bardoxolone methyl capsules
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 202 people
- Sponsor
- Biogen
Pulmonary Hypertension Outcome Assessment
Zürich Pulmonary Hypertension Outcome Assessment Cohort
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of PH.
- Trial name
- ZHPHCohort (NCT02249806)
- Testing
- PH target therapy according to physician
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Idiopathic Pulmonary Arterial Hypertension
Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
This study will be performed based on a retrospective analysis of the cases of 150-170 patients with IPAH observed at the Research Institute of Clinical Cardiology over the past 10 years, for a comparative assessment of the…
- Trial name
- NCT06587074
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Russian Cardiology Research and Production Center
Idiopathic Pulmonary Arterial Hypertension.
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
The purpose of this study is to determine if dynamic hyperinflation seen in patients with idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.
- Trial name
- NCT02108743
- Testing
- Albuterol.
- Where
- United States
- Sponsor
- American Medical Association Foundation
Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic
Medication Reconciliation in Pulmonary Hypertension
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex…
- Conditions
- Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic, Pulmonary Arterial Hypertension
- Trial name
- OPTICARE-HTP (NCT04744584)
- Testing
- Medication reconciliation
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
The purpose of this study is to test new technology and health coaching aimed to help people with PAH become more physically active in their daily lives.
- Trial name
- NCT05521113
- Testing
- Home Rehabilitation Monitoring System, Health coaching calls
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, NYHA
- Trial name
- NCT07797166
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini